GLP-1 Peptide Atlas, by Delfa

← Trials/Trial dossier/NCT06273163

TerminatedPhase NA

Identifying Strategies to Curtail Weight Regain After GLP-1 Receptor Agonist Treatment Cessation

Lead sponsor

University of Texas Southwestern Medical Center

Asset

GLP-1 / incretin class catch-all

Listed sites

Recruiting sites

—

Enrollment

actual

Study population

Obesity / overweight

Key I/E criterion

—

Primary endpoints

•Intervention Adherence•PGI, change

Footprint

Where this trial recruits

Site locations as reported to ClinicalTrials.gov. Site count is not enrollment count; per-site enrollment is not available from source.

Identifiers

Registered as

NCT IDNCT06273163

Org study IDSTU-2023-1168

Timeline

Milestones

Study first posted2024-02-22actual

Study start2024-03-05actual

Primary completion2025-08-05actual

Study completion2025-08-05actual

Last update posted2025-10-15actual

Assets

Investigational agents

GLP-1 / incretin class catch-all

Study populations

Who this study enrolls

Obesity / overweight

Eligibility

Who can enroll

Minimum age18 Years

SexAll

Healthy volunteersNot accepted

Inclusion criteria

•18 years of age or older;

•ability to read, write, and speak English;

•ability to provide informed consent;

•greater than 10% GLP-1 Receptor Agonist induced weight loss

•less than 30-days since GLP-1 Receptor Agonist cessation;

•willing to participate.

Exclusion criteria

•major psychiatric illness or substance misuse that could impair ability to participate;

•presence of a medical condition or dietary restriction precluding eating study meals or weight loss (e.g., medical condition requiring liquid diet, pregnancy, eating disorder);

•participation in a study or program involving medically tailored meals or Noom® within the past 12-months.

Endpoints (5)

What's being measured

Protocol endpoints and posted registry outcome measures, grouped into outcome categories. Composite endpoints show their component event types. Standard codes (LOINC, SNOMED CT) are shown where available.

Coverage by outcome category

Patient-reported / QoL

Weight & body composition

Other clinical outcomes

Other (unclassified)

Weight & body composition

1 endpoint

Secondary/protocol endpoint

Percent weight loss maintained

Time frame:4-months

Body weight, % change

percent change from baseline, improvement

Patient-reported / QoL

2 endpoints

Primary/protocol endpoint

Intervention Adherence

Time frame:4-months

descriptive

Primary/protocol endpoint

Intervention Satisfaction

Time frame:4-months

PGI, change

descriptive, improvement

Other clinical outcomes

1 endpoint

Secondary/protocol endpoint/low confidence

Diet quality

Time frame:4-months

change from baseline, improvement

Other (unclassified)

1 endpoint

Other/protocol endpoint/low confidence

Incremental cost effective ratio (ICER)

Time frame:4-months

descriptive

Provenance

Sources

Trial identity, design, statusClinicalTrials.gov API v2

Snapshot dateJuly 1, 2026

Endpoint classificationDelfa endpoint taxonomy v2 (May 13, 2026)

Results tableno registry results posted yet

Trial facts come from public ClinicalTrials.gov records. Endpoint categories are Delfa's classification of those records, not a ClinicalTrials.gov field. All figures reflect the July 1, 2026 snapshot.